醫(yī)藥行業(yè)伴隨診斷專題報(bào)告伴隨診斷借靶向治療東風(fēng)，促精準(zhǔn)醫(yī)療之勢(shì)

1、目錄圖表目錄...................................................................................................................................................................................31.伴隨靶向治療實(shí)現(xiàn)個(gè)體化治療，伴隨診斷助力精準(zhǔn)醫(yī)療發(fā)展......

2、................................................................................51.1伴隨診斷配套靶向治療，打造個(gè)性化治療新理念................................................................................................51.2二十年來(lái)伴隨靶向藥迅速發(fā)展，伴

3、隨診斷成IVD行業(yè)發(fā)展最快的領(lǐng)域之一............................................61.3四大技術(shù)熒光PCR應(yīng)用最廣，NGS代表未來(lái)發(fā)展方向....................................................................................61.4伴隨診斷在腫瘤領(lǐng)域應(yīng)用最為廣泛..........................

4、.................................................................................................81.5FDA出臺(tái)特定的監(jiān)管文件，國(guó)內(nèi)依照體外診斷產(chǎn)品注冊(cè)..................................................................................82.全球伴隨診斷市場(chǎng)以

5、超過(guò)20%的增速達(dá)到30億美元，國(guó)內(nèi)龍頭初顯.....................................................................92.1全球伴隨診斷市場(chǎng)以超過(guò)20%的增速達(dá)到30億美元.........................................................................................92.2市場(chǎng)與政策雙重導(dǎo)

6、向，診斷巨頭與制藥公司合作開(kāi)發(fā)是主導(dǎo)方向..............................................................102.3國(guó)際伴隨診斷市場(chǎng)眾多巨頭匯聚伴隨診斷...........................................................................................................122.4國(guó)內(nèi)伴

7、隨診斷行業(yè)百花齊鳴，產(chǎn)品眾多................................................................................................................132.5業(yè)務(wù)集中于伴隨診斷領(lǐng)域的診斷公司成長(zhǎng)速度.....................................................................

8、.............................143.五大因素驅(qū)動(dòng)全球伴隨診斷行業(yè)快速發(fā)展....................................................................................................................143.1基礎(chǔ)研究端：生物標(biāo)志物的不斷發(fā)現(xiàn)帶動(dòng)伴隨診斷產(chǎn)品開(kāi)發(fā)......................

9、.................................................143.2需求端：腫瘤患者基數(shù)大，新增數(shù)量多帶動(dòng)潛在用戶的增加.......................................................................153.3藥物端：國(guó)內(nèi)外靶向藥的廣泛使用直接推動(dòng)伴隨診斷行業(yè)增長(zhǎng).....................................

10、..............................163.4平臺(tái)端：NGS逐漸成熟，伴隨診斷的商業(yè)化能力有望進(jìn)一步釋放............................................................183.5政策端：國(guó)家明確鼓勵(lì)精準(zhǔn)醫(yī)療迅速發(fā)展.........................................................................

11、..................................204.NGS多基因檢測(cè)成為未來(lái)發(fā)展趨勢(shì)，液態(tài)活檢被廣泛看好......................................................................................214.1多基因聯(lián)合檢測(cè)優(yōu)勢(shì)顯著，NGS未來(lái)前景看好............................................

12、.....................................................214.2液體活檢有望脫穎而出，廣泛應(yīng)用于臨床...........................................................................................................225.綜合“技術(shù)創(chuàng)新、產(chǎn)品管線、渠道建設(shè)”三個(gè)維度分析，擇優(yōu)選取優(yōu)質(zhì)伴隨

13、診斷標(biāo)的..................................245.1艾德生物——最全的產(chǎn)品線構(gòu)建護(hù)城河，技術(shù)創(chuàng)新催化市場(chǎng)擴(kuò)容..............................................................245.1.1以7大技術(shù)平臺(tái)為基礎(chǔ)打造19個(gè)產(chǎn)品管線.............................................................

14、................................245.1.2國(guó)內(nèi)首款液體活檢產(chǎn)品獲批，NGS腫瘤檢測(cè)產(chǎn)品“特別審批”....................................................255.1.3營(yíng)銷體系強(qiáng)大，多方合作開(kāi)拓市場(chǎng)...............................................................................

15、..............................265.2芝友醫(yī)療——多款產(chǎn)品獲批，擁有國(guó)內(nèi)首家自動(dòng)化CTC檢測(cè)設(shè)備............................................................265.2.1擁有2個(gè)技術(shù)平臺(tái)，12款產(chǎn)品獲批上市.......................................................................

16、............................275.2.2重點(diǎn)發(fā)展液體活檢，CTCBIOPSY是首個(gè)獲批的自動(dòng)化CTC檢測(cè)設(shè)備........................................275.2.3積極拓展渠道，產(chǎn)品陸續(xù)進(jìn)入300多家醫(yī)院....................................................................................

17、......285.3百傲科技——專注個(gè)體化用藥基因診斷18年，邁入行業(yè)第一梯隊(duì)...........................................................285.3.1產(chǎn)品鏈環(huán)環(huán)相扣，PCR、基因芯片及芯片識(shí)讀儀三足鼎立................................................................295.3.2自動(dòng)化設(shè)備投入使用，4款試劑盒進(jìn)入

18、注冊(cè)報(bào)證階段.........................................................................305.3.3多方位尋找營(yíng)銷突破點(diǎn)，提高銷售能力....................................................................................................305.4燃石醫(yī)學(xué)——獲批“NGS

19、伴隨診斷第一證”，積極合作創(chuàng)新收.................................................................305.4.1擁有中國(guó)第一間獲CLIA認(rèn)證的ctDNA和NGS臨床檢測(cè)實(shí)驗(yàn)室主營(yíng)個(gè)性化液體活檢與基因檢測(cè)。......................................................................................

20、.......................................................................................315.4.2斬獲“國(guó)內(nèi)NGS伴隨診斷產(chǎn)品第一證”，積極合作創(chuàng)新收............................................................316.風(fēng)險(xiǎn)提示................................

21、.......................................................................................................................................................31圖表42.百傲科技?xì)w母凈利潤(rùn)增速超30%...............................................

22、....................................................28圖表43.百傲科技銷售毛利率超87%..................................................................................................................29圖表44.百傲科技21種主要產(chǎn)品獲批..............

23、......................................29圖表45.百傲科技5種最新項(xiàng)目研發(fā)成績(jī).................................................30圖表46.百傲科技各個(gè)突擊，尋找營(yíng)銷增長(zhǎng)點(diǎn).............................................30圖表47.燃石醫(yī)學(xué)與4家制藥、診斷巨頭合作.....................